American Association for Cancer Research
Browse

sorry, we can't preview this file

26433230bcd210142-sup-271046_2_supp_7381168_qz4wfh.docx (15.55 kB)

Supplemental Table 2A&2B from Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy

Download (15.55 kB)
journal contribution
posted on 2023-04-04, 01:05 authored by Roni Tamari, Ioannis Politikos, David A. Knorr, Santosha A. Vardhana, Jennifer C. Young, LeeAnn T. Marcello, Sital Doddi, Sean M. Devlin, Lakshmi V. Ramanathan, Melissa S. Pessin, Erica Dunn, Meighan Palazzo, Christina D. Bravo, Genovefa A. Papanicolaou, Mini Kamboj, Miguel Angel Perales, David J. Chung, Gunjan L. Shah

2A- MVA for the whole cohort 2B-MVA for patients who underwent allo-HCT only

Funding

NIH

NCI Cancer Center Support Grant

Society of Memorial Sloan Kettering

NCI

Leukemia and Lymphoma Society

Pershing Square Sohn Cancer Research Alliance

Conrad Hilton Foundation

History

ARTICLE ABSTRACT

Cellular therapies including allogeneic hematopoietic cell transplant (allo-HCT) and autologous hematopoietic cell transplant (auto-HCT) and chimeric antigen receptor (CAR) T-cell therapy render patients severely immunocompromised for extended periods after therapy, and data on responses to COVID-19 vaccines are limited. We analyzed anti–SARS-CoV-2 spike IgG Ab (spike Ab) titers and neutralizing Ab among 217 recipients of cellular treatments (allo-HCT, n = 149; auto-HCT, n = 61; CAR T-cell therapy, n = 7). At 3 months after vaccination, 188 patients (87%) had positive spike Ab levels and 139 (77%) had positive neutralization activity compared with 100% for both in 54 concurrent healthy controls. Time from cellular therapy to vaccination and immune recovery post–cellular therapy were associated with response. Vaccination against COVID-19 is an important component of post–cellular therapy care, and predictors of quantitative and qualitative response are critical in informing clinical decisions about optimal timing of vaccines and the requirement for booster doses. Identifying predictors of response to vaccination against SARS-CoV-2 in patients following cellular therapy is critical to managing this highly vulnerable patient population. To date, this is the most comprehensive study evaluating quantitative and qualitative responses to vaccination, providing parameters most predictive of response and potentially informing booster vaccination strategies.See related article by Chung et al., p. 568.This article is highlighted in the In This Issue feature, p. 549

Usage metrics

    Blood Cancer Discovery

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC